Human proteinopathies are diseases caused by the expression of defective gene products. In some cases, these diseases involve the degradation of mutant but otherwise functional proteins by the quality control system of the secretory pathway. Our recent study identified two proteins that play a role in post-endoplasmic reticulum (ER) quality control and are potential targets for therapeutic treatment of several proteinopathies 1 .
Secretory and membrane proteins acquire their native structure in the ER, where molecular chaperones and folding enzymes assist the folding process. Despite the presence of a large number of ERresident folding factors, the folding process may eventually fail. Non-native features such as exposed hydrophobic patches, unpaired cysteine residues and non-native peptidyl-prolyl bonds may alert the ER quality control machinery to ensure that terminally misfolded polypeptides are not released into the secretory pathway (ER QC, yellow arrow in the schematic). Rather, they are dislocated into the cytosol and ultimately degraded by the ubiquitin-proteasome system in a series of events collectively defined as ER-associated degradation (ERAD, red arrow) 2 
.
Intermediates of folding programs, or individual subunits of oligomeric complexes must also be retained in the ER, but they must be preserved from premature degradation. The presence of ionizable residues in the intramembrane portion is a common feature of many subunits of oligomeric complexes. These residues play an essential role in the biogenesis of complexes such as the T-cell receptor (TCR), the natural killer-cell immunoglobulin-like receptor (KIR) and the NKG2D receptor by promoting retention in the folding compartment until association of the appropriate binding partners [3] [4] [5] . However, mutations introducing ionizable residues in the transmembrane domain of secretory proteins may have deleterious consequences such as the inappropriate selection for degradation of these otherwise functional gene products 6, 7 . For example, Ehlers-Danlos syndrome and idiopathic epilepsy are caused by the inappropriate degradation of the zinc transporter protein ZIP13 and the GABAA receptor, respectively, in which an alanine or glycine to aspartic acid mutation is introduced in the transmembrane portion [8] [9] [10] .
Understanding the molecular details of quality control mechanisms operating in living cells is fundamental for the development of new pharmacological treatments that rescue mutant, but functional polypeptides from degradation and promote their transport to the proper site of activity. This would ameliorate the outcome of several human proteinopathies 11, 12 .
A recent study in our lab led to the identification of a new quality control checkpoint operating in the secretory pathway that is alerted by the presence of ionizable residues in the transmembrane region. The peculiarity of this novel checkpoint is that it intervenes after release of the mutant protein from the ER 1 .
To monitor the consequences of ionizable transmembrane residues, we constructed four different model polypeptides. The chimeras used in our study were type I membrane proteins where the luminal portion was constituted by a folding defective (Null Hong Kong variant [NHK] of human α1-anti trypsin [α1AT]) or a folding competent (α1AT) ectodomain fused to the C-terminal portion of CD3δ, a subunit of the TCR. The transmembrane region of CD3δ naturally contains an ionizable aspartic acid residue at position 6 (chimeras NHKc and α1ATc), which was mutated into an uncharged alanine residue (chimeras NHKcD6A and α1ATcD6A) (Figure 1 ).
The chimeras displaying the folding-defective ectodomain, NHKc and NHKcD6A, were retained in the ER and were efficiently cleared by the cytosolic proteasome. The presence or absence of the intramembrane ionizable residue made little difference, if at all. This was expected since the ER QC machinery proficiently recognizes misfolded polypeptides and targets them for ERAD.
On the other hand, the intramembrane ionizable residue substantially affected the fate of the chimeras displaying a folded ectodomain as the folding-competent chimera lacking the ionizable residue in the intramembrane domain (α1ATcD6A) was efficiently transported to the Golgi, whereas the chimera displaying the intramembrane ionizable residue (α1ATc) was halted in a compartment located between the ER and the Golgi.
The novel, post-ER QC checkpoint relies on the multifunctional, cytosolic AAA ATPase p97 13 and UDPglucose:glycoprotein glucosyl transferase (UGGT1), a luminal ER-resident enzyme responsible for the reglucosylation of N-linked sugars, a process determining glycopolypeptides retention in the calnexin cycle 14 . Consistently, pharmacological inhibition of p97 with N2,N4-dibenzylquinazoline-2,4-diamine (DBeQ), a selective ATP-competitive p97 inhibitor 15 , or individual silencing of p97 and UGGT1 expression restored the Golgi transport of α1ATc. As such, p97 and UGGT1 emerge as novel pharmacologic targets for loss-of-function diseases.
UGGT1 and p97 are soluble proteins of the ER lumen and of the cytosol, respectively. The membrane-bound linker connecting them in a functional post-ER QC complex remains to be identified. The multispanning protein Bap31 is a candidate protein for this function. Bap31 is involved in ERAD and in vesicular transport in the early secretory pathway 16, 17 . Importantly, it has been reported that Bap31 preferentially interacts with charged intramembrane residues 18 . In our tests, silencing of Bap31 did not rescue the α1ATc trafficking. This could be explained by residual Bap31 that might ensure post-ER retention of α1ATc. Future perspectives include the knockout of Bap31 and other putative components operating in post-ER quality control using a recently developed, powerful gene-editing technology, the CRISPR/Cas9 technology 19 .
The characterization of mechanisms regulating protein quality control will help in the identification of new targets for pharmacologic treatment of human proteinopathies, i.e., of diseases caused by expression of defective gene products.
